# US 2024/0189269 A1 · Pharmaceutical composition for suppressing tmprss2 expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189269 A1
- Document ID: US20240189269A1
- Status: Published application
- Kind: A1
- Application number: 18/552,289
- Filed: 2021-12-03
- Published: 2024-06-13
- Earliest claimed: 2021-03-26
- Assignees: Tokyo Institute of Technology; SBI Pharmaceuticals Co., Ltd.
- Applicants: Tokyo Institute of Technology; SBI Pharmaceuticals Co., Ltd.
- Inventors: Shunichiro Ogura; Motowo Nakajima; Masahiro Ishizuka; Takuya Ishii; Hideo Imazato
- Web page: https://patentgrep.com/patent/US20240189269A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/221: with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A61K 31/295: Iron group metal compounds
- A61K 33/26: Iron; Compounds thereof
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The object of the present invention is to search for a compound that may suppress the expression of TMPRSS2 in a cell or tissue. The expression of TMPRSS2 in a cell or tissue is suppressed by 5-aminolevulinic acids.

## Claims

### Claim 1

A pharmaceutical composition for suppressing the expression of type II transmembrane serine protease (TMPRSS2), comprising a compound shown by the following Formula (I):
R1—NHCH2COCH2CH2COOR2 (I)
wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group; or a salt or an ester thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1 for further suppressing the expression of angiotensin converting enzyme 2 (ACE2) in addition to said TMPRSS2.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, characterized in that
R1 is selected from the group consisting of a hydrogen atom, an alkanoyl group having 1-8 carbons, and an aroyl group having 7-14 carbons, and
R2 is selected from the group consisting of a hydrogen atom, a linear or branched alkyl group having 1-8 carbons, a cycloalkyl group having 3-8 carbons, an aryl group having 6-14 carbons, and an aralkyl group having 7-15 carbons.

### Claim 4

The pharmaceutical composition according to claim characterized in that R1 and R2 are hydrogen atoms.

### Claim 5 (depends on 1)

The pharmaceutical composition according to any one of claim 1, characterized in that it further contains one or two or more types of metal-containing compounds.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, characterized in that the metal-containing compound is a compound containing iron, magnesium, zinc, nickel, vanadium, copper, chromium, molybdenum, or cobalt.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, characterized in that the metal-containing compound is a compound containing iron.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, characterized in that said compound containing iron is sodium ferrous citrate.

### Claim 9 (depends on 1)

A method for prevention or treatment of a disease related to expression of TMPRSS2 or ACE2 in a cell or tissue in a subject, comprising administering to the subject the pharmaceutical composition according to claim 1.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said disease related to expression of TMPRSS2 or ACE2 is an infection by a virus that infects by utilizing TMPRSS2 or ACE2.

### Claim 11

(canceled)

### Claim 12

A method for suppressing the expression of type II transmembrane serine protease (TMPRSS2), comprising a step of applying to a subject an effective amount of a compound shown by the following Formula (I):
R1—NHCH2COCH2CH2COOR2 (I)
wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group;
or a salt or an ester thereof.

### Claim 13

A kit for suppressing the expression of TMPRSS2, characterized in that it comprises a compound shown by the following Formula (I):
wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group);
or a pharmaceutically acceptable salt or ester thereof.
